KLK3 and prostate carcinoma: The most sensitive biomarker for prostate cancer recurrence after radical prostatectomy or radiotherapy is serum prostate specific antigen (PSA).1 However, the evidence on the association of biochemical recurrence (BCR) (ie, PSA rise after treatment with curative intent) with prostate cancer survival is limited.